Southampton-based Synairgen announces positive results from its Phase II of SNG001 in hospitalised Covid-19 patients.
SNG001 is an investigational drug that is also being studied for asthma and COPD. It is an inhaled formulation of interferon beta.
Synairgen CEO Richard Marsden said: "We are all delighted with the trial results announced today, which showed that SNG001 greatly reduced the number of hospitalised COVID-19 patients who progressed from ‘requiring oxygen’ to ‘requiring ventilation’.
"It also showed that patients who received SNG001 were at least twice as likely to recover to the point where their everyday activities were not compromised through having been infected by SARS-CoV-2.
In addition, SNG001 has significantly reduced breathlessness, one of the main symptoms of severe Covid-19.
This assessment of SNG001 in COVID-19 patients could signal a major breakthrough in the treatment of hospitalised COVID-19 patients.
"Our efforts are now focused on working with the regulators and other key groups to progress this potential COVID-19 treatment as rapidly as possible."
Chief investigator of the trial and University of Southampton professor of respiratory medicine Tom Wilkinson added: "We are delighted with the positive data produced from this trial.
"The results confirm our belief that interferon beta, a widely known drug that, by injection, has been approved for use in a number of other indications, has huge potential as an inhaled drug to be able to restore the lung’s immune response, enhancing protection, accelerating recovery and countering the impact of SARS-CoV-2 virus.”
Synairgen and the University of Southampton are also studying SNG001 in the early stages of Covid-19 disease in a unique, at-home virtual trial.